Autolus Therapeutics plc AUTL
Autolus Therapeutics plc (Nasdaq: AUTL) is an oncology drug developer. Its lead program, AUCATZYL (obecabtagene autoleucel, obe-cel), is in Phase 2 for Adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Its next catalyst on record is AUTO8 (ALARIC): Initial Phase 1 data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AUTO8 (ALARIC) — Initial Phase 1 data (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AUCATZYL (obe-cel) | Adult r/r B-ALL | cell therapy | Approved |
| Obe-cel (LUMINA) | Refractory lupus nephritis | cell therapy | Phase 2 |
| Obe-cel (CATULUS) | Pediatric B-ALL and B-NHL | cell therapy | Phase 2 |
| Obe-cel (CARLYSLE) | Severe refractory systemic lupus erythematosus | cell therapy | Phase 1 |
| Obe-cel (BOBCAT) | Refractory progressive multiple sclerosis | cell therapy | Phase 1 |
| AUTO8 (ALARIC) | Light-chain amyloidosis | cell therapy | Phase 1 |
Recent results and decisions
- Apr 8, 2026positive Pediatric CATULUS data (ASH 2025 poster re-shown at investor event): ORR 95.5% (21/22), CR 90.9%, all responders MRD-negative, Grade >=3 CRS and ICANS 8.7% each.
At median follow-up (8.8 months), 21/22 patients responded to obe-cel; the ORR was 95.5% CI (95% CI: 77.2–99.9)
Filing - Jan 12, 2026positive CATULUS Phase 1 pediatric r/r B-ALL: ORR 95.5% (CR 90.9%) at median 8.8 months follow-up with low rates of high-grade CRS and ICANS (ASH 2025).
Obe-cel demonstrated high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%.
Filing - Nov 12, 2025positive CARLYSLE 50M-cell cohort (n=6): DORIS in 5/6 (83.3%) and complete renal response in 3/6 (50%), no ICANS or high-grade CRS (ACR 2025 data).
Achievement of DORIS in 83.3% (n=5/6) of patients
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.